Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -72.02% is 34% below its 5-year average of -53.60%, near the low end of its 5-year range (-75.52%–-30.62%).
As of the fiscal period ended Friday, July 31, 2026. 3.17% below its 12-month average of -69.81%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-07-31): -72.02%.
RETURN ON EQUITY (ROE)
-72.02%
RETURN ON EQUITY (ROE) AVG TTM
-69.81%
RETURN ON EQUITY (ROE) AVG 3Y
-60.87%
RETURN ON EQUITY (ROE) AVG 5Y
-53.60%
RETURN ON EQUITY (ROE) AVG 10Y
-77.17%
RETURN ON EQUITY (ROE) AVG 15Y
-107.78%
RETURN ON EQUITY (ROE) AVG 20Y
-170.23%
CURRENT VS TTM AVG
-3.17%
CURRENT VS 3Y AVG
-18.32%
CURRENT VS 5Y AVG
-34.38%
CURRENT VS 10Y AVG
+6.67%
CURRENT VS 15Y AVG
+33.18%
CURRENT VS 20Y AVG
+57.69%
SECTOR MEDIAN · HEALTHCARE
-37.94%
median of 451 covered companies
CURRENT VS SECTOR MEDIAN
-89.83%
vs the sector median at left
Anixa Biosciences, Inc.
Market Cap
$100.16M
Return on Equity (ROE)
-72.02%
TTM Avg
-69.81%
3Y Avg
-60.87%
5Y Avg
-53.60%
Market Cap
$101.03M
Return on Equity (ROE)
-103.31%
TTM Avg
-140.03%
3Y Avg
-67.31%
5Y Avg
-49.97%
Market Cap
$104.47M
Return on Equity (ROE)
-116.28%
TTM Avg
-71.19%
3Y Avg
-41.66%
5Y Avg
-29.50%
Market Cap
$102.66M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$92.54M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$91.51M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$109.38M
Return on Equity (ROE)
-60.82%
TTM Avg
-19.88%
3Y Avg
-19.08%
5Y Avg
-15.27%
Market Cap
$108.02M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$89.11M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anixa Biosciences, Inc. (ANIX) | $100.16M | -72.02% | -69.81% | -60.87% | -53.60% |
| Korro Bio, Inc. (KRRO)vs › | $101.03M | -103.31% | -140.03% | -67.31% | -49.97% |
| Definitive Healthcare Corp. (DH)vs › | $104.47M | -116.28% | -71.19% | -41.66% | -29.50% |
| The Joint Corp. (JYNT)vs › | $102.66M | 23.96% | -4.38% | -11.56% | 6.84% |
| Biomea Fusion, Inc. (BMEA)vs › | $92.54M | -268.09% | -238.76% | -155.55% | -124.74% |
| electroCore, Inc. (ECOR)vs › | $91.51M | N/A | 329.82% | 69.21% | 21.28% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $109.38M | -60.82% | -19.88% | -19.08% | -15.27% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.02M | -99.67% | -40.73% | 98.81% | 13.93% |
| Conexeu Sciences Inc. (CNXU)vs › | $89.11M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $89.36M | -150.95% | -77.89% | -62.90% | -47.80% |
ROE
-72.0%
ROA
-69.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -72.02% |
| 2026-04-30 | -69.60% |
| 2026-01-31 | -68.37% |
| 2025-10-31 | -72.07% |
| 2025-07-31 | -66.98% |
| 2025-04-30 | -75.52% |
| 2025-01-31 | -70.70% |
| 2024-10-31 | -63.47% |
| 2024-07-31 | -57.41% |
| 2024-04-30 | -49.67% |
| 2024-01-31 | -43.67% |
| 2023-10-31 | -40.31% |
| 2023-07-31 | -41.52% |
| 2023-04-30 | -40.40% |
| 2023-01-31 | -43.49% |
| 2022-10-31 | -46.80% |
| 2022-07-31 | -44.57% |
| 2022-04-30 | -48.86% |
| 2022-01-31 | -42.91% |
| 2021-10-31 | -36.56% |
| 2021-07-31 | -30.62% |
| 2021-04-30 | -24.97% |
| 2021-01-31 | -70.84% |
| 2020-10-31 | -114.35% |
| 2020-07-31 | -114.66% |
| 2020-04-30 | -178.93% |
| 2020-01-31 | -171.87% |
| 2019-10-31 | -222.47% |
| 2019-07-31 | -256.31% |
| 2019-04-30 | -278.14% |
| 2019-01-31 | -310.98% |
| 2018-10-31 | -257.53% |
| 2018-07-31 | -165.64% |
| 2018-04-30 | -112.04% |
| 2018-01-31 | -81.70% |
| 2017-10-31 | -63.22% |
| 2017-07-31 | -77.82% |
| 2017-04-30 | -99.74% |
| 2016-10-31 | -508.01% |
| 2016-07-31 | -306.20% |
| 2016-04-30 | -225.00% |
| 2016-01-31 | -187.25% |
| 2015-10-31 | -27.29% |
| 2015-07-31 | -54.02% |
| 2015-04-30 | -17.55% |
| 2015-01-31 | -27.12% |
| 2014-10-31 | -239.58% |
| 2012-01-31 | -913.06% |
| 2011-10-31 | -697.34% |
| 2011-07-31 | -254.95% |
| 2011-04-30 | -169.43% |
| 2011-01-31 | -193.92% |
| 2010-10-31 | -112.60% |
| 2010-07-31 | -531.02% |
| 2010-04-30 | -345.75% |
| 2010-01-31 | -384.73% |
| 2009-10-31 | -370.35% |
| 2009-07-31 | -156.02% |
| 2009-04-30 | -727.09% |
| 2008-10-31 | -336.46% |
| 2008-07-31 | -80.37% |
| 2008-04-30 | -43.13% |
| 2008-01-31 | -34.07% |
| 2007-10-31 | -458.15% |
| 2007-07-31 | -404.12% |
| 2007-04-30 | -433.78% |
| 2007-01-31 | -484.09% |
| 2006-10-31 | -592.97% |
| 2006-07-31 | -530.48% |
| 2006-04-30 | -446.71% |
| 2006-01-31 | -399.13% |
| 2005-10-31 | -398.14% |
| 2005-07-31 | -277.84% |
| 2005-04-30 | -227.80% |
| 2005-01-31 | -184.86% |
| 2004-10-31 | -179.43% |
| 2004-07-31 | -168.06% |
| 2004-04-30 | -134.94% |
| 2004-01-31 | -178.51% |
| 2003-10-31 | -156.64% |
| 2003-07-31 | -187.46% |
